Pilot Study of DRibble Vaccine for Prostate Cancer Patients

Completed · Phase 1

Conditions studied: Adenocarcinoma of the Prostate

In brief

This is a pilot study of the DRibble vaccine in patients with advanced prostate cancer.

Key facts

Study ID

NCT02234921

Run by

UbiVac

People needed

3

Starts

2014-10-24

Expected to finish

2018-08-15

Last updated by the study team

2018-10-11

Who can join

Age: any. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Subjects have measurable or evaluable metastatic castrate resistant adenocarcinoma of the prostate with progression after chemotherapy, combined androgen blockade and/or peripheral androgen or androgen receptor suppression. Either histologic or serum marker diagnosis is acceptable.
• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
• Ability to give informed consent and comply with the protocol.
• Prior therapy with investigational agents must have been completed at least 3 weeks prior to study enrollment.
• Patients must have normal organ and marrow function as determined by routine blood tests

You may not qualify if…

• Active autoimmune disease except vitiligo or hypothyroidism.
• Active other malignancy.
• Known HIV positive and/or Hepatitis B or C positive.
• Other medical or psychiatric conditions that in the opinion of the Principal Investigator would preclude safe participation in protocol.

Where it is running

• Providence Health & Services — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.